Posted this in another thread but thought let’s start a thread exclusively for valuations.
Mine:
Approx 6000 patients in the USA. Will assume 50% market penetration (which is high) due to how active the Retts community is and how long they’ve been looking for treatments.
3000 patients at $375,000 USD p/a = $1,125,000,000 revenue for Acadia.
Based on Neurens royalties structure:
The first $250,000 USD = 10% of sales = $25 million
USD$250,000-$500,000 USD = 12% of sales = $30 million USD
$500,000-$750,000 USD = 14% of sales = $35 million USD
>$750,000 USD = 15% of sales = $56.25M USD
Total royalties p/a = $146 million USD.
Ex rate 0.70 = $208M AUD
Tax rate 30%
After tax profit (I know there will be business running costs but they won’t be much) = $146M AUD
Shares on issue = 129M
Earnings per share = $1.13
Industry average PE ratio = 26 but let’s use 20 to be conservative
Valuation = $22.67 just based off neurens royalties from Acadia in the USA, Not factoring in anything from rest of the world
Let’s compare valuations based off Acadias price for Daybue
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.77 |
Change
-0.200(1.00%) |
Mkt cap ! $2.535B | |||
| Open | High | Low | Value | Volume |
| $19.96 | $19.96 | $19.71 | $1.072M | 54.12K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 254 | $19.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.79 | 428 | 7 |
View Market Depth
| Last trade - 11.31am 05/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |